Literature DB >> 3493450

Fine analysis of cytolytic and natural killer T lymphocytes in the CSF in multiple sclerosis and other neurologic diseases.

W E Weber, W A Buurman, M M Vandermeeren, R H Medaer, J C Raus.   

Abstract

Cytolytic T lymphocyte precursors (CTL-p) and natural killer precursors (NK-p) in the CSF of 15 MS patients and 11 patients with other neurologic disorders (OND) were quantitatively assessed, using a T-lymphocyte microculture system that allows clonal expansion of all human T cells. CSF CTL-p and NK-p frequencies were higher in patients with OND of inflammatory nature than in patients with noninflammatory OND. In all MS patients, these frequencies were higher in the CSF than in their peripheral blood. Surprisingly, in all patients studied, the CSF contained a substantial number of CTL-p with a helper (CD4+) phenotype.

Entities:  

Mesh:

Year:  1987        PMID: 3493450     DOI: 10.1212/wnl.37.3.419

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

2.  Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.

Authors:  M Saraste; H Irjala; L Airas
Journal:  Neurol Sci       Date:  2007-06-30       Impact factor: 3.307

3.  Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals.

Authors:  F T Rotteveel; B Kuenen; I Kokkelink; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

Review 4.  Natural Killer Cells in Multiple Sclerosis: Entering the Stage.

Authors:  Jarne Beliën; An Goris; Patrick Matthys
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

5.  Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression.

Authors:  Liesbet M Peeters; Marjan Vanheusden; Veerle Somers; Bart Van Wijmeersch; Piet Stinissen; Bieke Broux; Niels Hellings
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.